Selank Peptide: Status, Evidence and Sellers

Selank is a synthetic chain of seven amino acids built on tuftsin, a short peptide the immune system already uses [4] [5]. It was developed in Russia, where most of its research has been published, and in the United States it turns up at wellness clinics and research-chemical sites as an anti-anxiety nootropic. It is often sold beside semax, including as a 50:50 blend in nasal sprays and injections [9].

Unlike most peptides on these menus, selank has been given to patients with a diagnosis. Three small Russian studies set it against a benzodiazepine or added it to one, and reported that it eased anxiety about as well as the comparator or helped it work [1] [2] [3]. None of the studies we found used a placebo group, and none has been repeated outside the group that developed the compound.

Selank is not one of the six peptides in the interim HHS policy of October 28, 2026, so that policy does not cover it in any form [10]. FDA lists it among nominations for compounding that were withdrawn, noting that it lacks important safety information about selank in people [8].

How selank works is not settled. The Russian clinical group measured enkephalin activity in patients' blood and found it low at baseline and rising during treatment, which they proposed as one route to its calming effect [1]. Other work points to the immune system. In patients treated for 14 days the balance of inflammatory signaling molecules in the blood shifted [4], and in mice a single injection changed the activity of 34 of 84 inflammation genes in the spleen [5].

A 2021 review of sedative drugs grouped selank with phenibut as poorly studied Russian compounds thought to act through GABA, the brain's main calming signal, and noted that both are sold to US consumers as dietary supplements despite how little they have been studied [7]. GABA is the system benzodiazepines act on, which is why the comparison trials chose those drugs.

The largest study enrolled 62 people with generalized anxiety disorder or neurasthenia. Thirty took selank and 32 took medazepam, a benzodiazepine, and the authors reported that anxiety fell about equally in both groups, with selank also reducing fatigue [1]. A 2014 study of 60 patients with anxiety and somatoform disorders compared selank with phenazepam and reported a clear anti-anxiety effect that lasted a week after the last dose [2]. In a 2015 study, adding selank to phenazepam in 40 patients was compared with phenazepam alone in 30, and the combination produced fewer of the benzodiazepine's side effects, such as sedation and memory problems [3].

All three are published in Russian, and we read them only as abstracts, so we cannot check how patients were assigned, whether assessors knew who took what, or how dropouts were handled. Comparing with an active drug is a harder test than placebo, but without a placebo arm a study cannot show how much of the improvement any drug produced. The one study in healthy volunteers measured brain connectivity on a scanner, not anxiety or attention [6].

Grade C: a real human record in patients, from one research group and one literature, without a placebo-controlled trial or independent replication behind the anti-anxiety claim. Our evidence review covers the 2008 trial in more detail.

No dose of selank is approved in the United States, and the abstracts we read do not state the doses or routes used in the patient studies, so this page gives none. Clinic and vendor protocols for daily nasal sprays or injections do not come from a trial we could check.

What is sold here comes in two forms FDA documented in its 2026 review of semax: nasal sprays and injections, alone or mixed with semax [9]. Under the October 2026 HHS policy, even the semax half of such a blend falls outside the conditions, because the policy covers single-ingredient products only [10].

The patient studies describe selank as well tolerated, and the 2015 study reported that adding it reduced the benzodiazepine's side effects [3]. Those are small, short studies, and FDA's own assessment is that it lacks important information about selank's safety in humans [8]. Long-term use, use in pregnancy and interactions with other drugs have not been studied in the trials we found.

Because selank is thought to act on the same calming system as benzodiazepines and alcohol, combining them is a question for a prescriber. People already taking an anti-anxiety medicine should not stop or replace it with selank on their own, since benzodiazepines in particular need a supervised taper.

Selank is not named on the World Anti-Doping Agency's 2026 Prohibited List. That list's S0 class bans unnamed substances with no current approval from any government health authority for human use [11], so an athlete should ask their anti-doping organization before assuming it is permitted.